Recurrent or Metastatic Solid Tumors Clinical Trial
Official title:
A Phase 2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors
This study is designed to assess the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); non-squamous non-small cell lung cancer (NSCLC); and urothelial carcinoma (UC).
This study will evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in participants with recurrent or metastatic solid tumors previously treated with 1 or more systemic therapies for the selected tumor indication. The study will be divided into 2 parts: Stage 1 and Stage 2. Each cohort starts with Stage 1 and may continue to Stage 2 if sufficient safety and efficacy data are observed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02221960 -
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06093698 -
An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
|
Phase 1 |